List of Vitekta drug patents
Vitekta is owned by Gilead Sciences Inc.
Vitekta contains Elvitegravir.
Vitekta has a total of 6 drug patents out of which 0 drug patents have expired.
Vitekta was authorised for market use on 24 September, 2014.
Vitekta is available in tablet;oral dosage forms.
Vitekta can be used as treatment of hiv infection.
The generics of Vitekta are possible to be released after 26 April, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(3 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(3 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
Drugs and Companies using ELVITEGRAVIR ingredient
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
VITEKTA family patents
11
United States
8
Norway
8
Japan
8
European Union
4
Argentina
3
Peru
2
Spain
2
Hong Kong
2
Malaysia
2
Denmark
2
Russia
2
China
2
Brazil
2
Canada
2
New Zealand
2
Korea, Republic of
2
Cyprus
2
Portugal
2
Taiwan
2
Mexico
2
Australia
2
South Africa
2
Slovenia
1
Austria
1
Turkey
1
Czech Republic
1
RS
1
Poland
1
Germany
1
Croatia
1
Israel
1
Slovakia
1
Lithuania
1
Luxembourg
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic